Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 3:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment of Benign Prostatic Hyperplasia Clear all
Completed Phase 3 Interventional

The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score

NCT00540891
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
ALFUZOSIN
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older · Male only
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 7, 2007 · Synced Sep 24, 2026, 3:52 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

NCT00709488
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
Talaporfin sodium, Placement of device in prostate urethra, Transurethral illumination with light emitting diodes (Litx™ BPH Device)
Drug · Procedure · Device
Lead sponsor
Light Sciences Oncology
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Anchorage, Alaska • Los Angeles, California • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2012 · Synced Sep 24, 2026, 3:52 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)

NCT01912339
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptom
Interventions
Rezum System, Rigid Cystoscopy
Device · Procedure
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
50 Years and older · Male only
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
15
States / cities
Tucson, Arizona • Denver, Colorado • Aventura, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Sep 24, 2026, 3:52 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Prostate Artery Embolization for the Treatment of Benign Prostatic Hyperplasia

NCT03179228
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Prostate Embolization
Device
Lead sponsor
John D Louie
Other
Eligibility
50 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 24, 2026, 3:52 AM EDT
Not listed Not applicable Interventional

Safety and Effectiveness Study of the Zenflow Spring System

NCT04987138
View directory record Official record
Conditions
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
Interventions
Zenflow Spring System, Sham Procedure
Device
Lead sponsor
Zenflow, Inc.
Industry
Eligibility
45 Years and older · Male only
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Glenview, Illinois • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Sep 24, 2026, 3:52 AM EDT
Terminated Not applicable Interventional Results available

Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia

NCT01789840
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Embosphere Microspheres, TURP
Device · Procedure
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
50 Years to 79 Years · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
Long Beach, California • Los Angeles, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 24, 2026, 3:52 AM EDT
Completed Phase 2Phase 3 Interventional

Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)

NCT02637960
View directory record Official record
Conditions
Nocturia
Interventions
Fedovapagon 2 mg, Placebo
Drug
Lead sponsor
Vantia Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
48
States / cities
Anniston, Alabama • Goodyear, Arizona • Lincoln, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Sep 24, 2026, 3:52 AM EDT
Completed Not applicable Interventional Results available

The Safety and Effectiveness of UroLift: LIFT Pivotal Study

NCT01294150
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift System, Cystoscopy, Crossover
Device · Other
Lead sponsor
NeoTract, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
San Diego, California • San Jose, California • Englewood, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 24, 2026, 3:52 AM EDT
Terminated Phase 2 Interventional Results available

Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams

NCT02396420
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Embosphere Microspheres
Device
Lead sponsor
South Florida Medical Imaging, PA
Other
Eligibility
40 Years to 89 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Sep 24, 2026, 3:52 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

NCT03902080
View directory record Official record
Conditions
Overactive Bladder
Interventions
Vibegron, Placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
45 Years and older · Male only
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
75
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 24, 2026, 3:52 AM EDT
Withdrawn Phase 4 Interventional

The Combined Effect of Intravesical Botox Injections and HoLEP Surgery in Treating Benign Prostatic Hyperplasia and Overactive Bladder

NCT05393921
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Overactive Bladder
Interventions
Intravesical Botox injection
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Cleveland, Ohio • Lyndhurst, Ohio • Richmond Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 24, 2026, 3:52 AM EDT
Withdrawn Not applicable Interventional

Prostatic Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH)

NCT04563221
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
Prostatic artery embolization
Device
Lead sponsor
Andrew Picel
Other
Eligibility
45 Years to 85 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Sep 24, 2026, 3:52 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia

NCT00962390
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
S-equol, Placebo
Drug
Lead sponsor
Ausio Pharmaceuticals, LLC
Industry
Eligibility
50 Years and older · Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
5
States / cities
Huntsville, Alabama • Aventura, Florida • Clearwater, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Sep 24, 2026, 3:52 AM EDT
Completed No phase listed Observational Results available

GreenLight XPS Laser System Retrospective Chart Review

NCT02139969
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
GreenLight XPS Laser System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Male only
Enrollment
956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
5
States / cities
Mountain View, California • Atlanta, Georgia • Westland, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Sep 24, 2026, 3:52 AM EDT
Terminated No phase listed Observational

Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode

NCT02019030
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Not listed
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Loma Linda, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 24, 2026, 3:52 AM EDT
Completed Phase 3 Interventional Results available

The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months

NCT00224133
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Silodosin
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
50 Years and older · Male only
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
79
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2010 · Synced Sep 24, 2026, 3:52 AM EDT
Recruiting Phase 2 Interventional

Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer

NCT06161506
View directory record Official record
Conditions
Urinary Urge Incontinence, Stress Urinary Incontinence, Prostatic Hyperplasia
Interventions
Elidah Device
Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 24, 2026, 3:52 AM EDT
Recruiting Not applicable Interventional

5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy

NCT04288427
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Prostate Hyperplasia, Prostate Disease, Prostate Hypertrophy, Prostate Pain, Lower Urinary Tract Symptoms, Urinary Obstruction, Urinary Tract Disease
Interventions
Finasteride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 24, 2026, 3:52 AM EDT
Not listed Phase 4 Interventional

A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart

NCT00690950
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Dutasteride
Drug
Lead sponsor
Urologic Consultants of Southeastern PA
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Bala-Cynwyd, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2008 · Synced Sep 24, 2026, 3:52 AM EDT
Completed Phase 2Phase 3 Interventional

MCS in the Treatment of Lower Urinary Tract Symptoms

NCT01002417
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Interventions
MCS-2 15 mg/day, MCS-2 30 mg/day, Placebo
Drug
Lead sponsor
Health Ever Bio-Tech Co., Ltd.
Industry
Eligibility
40 Years and older · Male only
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Sep 24, 2026, 3:52 AM EDT
Active, not recruiting Not applicable Interventional

Investigation of Prostate Artery Embolization Compared to Holmium Laser Enucleation of Prostate

NCT05155891
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Embosphere Microspheres, HoLEP Procedure
Device · Procedure
Lead sponsor
University of Miami
Other
Eligibility
50 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 24, 2026, 3:52 AM EDT
Completed Not applicable Interventional Results available

Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)

NCT02026908
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Prostate Artery Embolization
Device
Lead sponsor
Northwestern University
Other
Eligibility
45 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Sep 24, 2026, 3:52 AM EDT
Completed Phase 4 Interventional Results available

Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)

NCT00939120
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Tolterodine ER 4mg, Placebo, Pre-randomization Dutasteride
Drug
Lead sponsor
Siami, Paul F., M.D.
Other
Eligibility
50 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Newburgh, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Sep 24, 2026, 3:52 AM EDT
Completed Phase 4 Interventional Results available

Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia

NCT00701779
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Tamsulosin
Drug
Lead sponsor
Siami, Paul F., M.D.
Other
Eligibility
50 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Sep 24, 2026, 3:52 AM EDT